Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury
Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal o...
Gespeichert in:
Veröffentlicht in: | Neuropharmacology 2024-12, Vol.261, p.110165 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 110165 |
container_title | Neuropharmacology |
container_volume | 261 |
creator | Pondelick, Abby M Moncayo, Lauren V Donvito, Giulia McLane, Virginia D Gillespie, James C Hauser, Kurt F Spiegel, Sarah Lichtman, Aron H Sim-Selley, Laura J Selley, Dana E |
description | Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism. |
doi_str_mv | 10.1016/j.neuropharm.2024.110165 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_39303855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39303855</sourcerecordid><originalsourceid>FETCH-pubmed_primary_393038553</originalsourceid><addsrcrecordid>eNqFj81OwzAQhC0kRMvPK6A9wiHBzk8TzkDLEYleOFWuvaEbJXZkO0XhtXhBXApnLrua1aeZWcZA8FRwsbhrU4Ojs8NOuj7NeFak4nAvT9hc1FWeVHxRzNi59y3nvKhFfcZm-X3O87os5-zrkby3imQga2CL4QPRQNghSBMokV1n9WRIATYNquDBNtCQebcd9VbDzXL9VmX8NtIaNHo0ngJ9Ht0i-ipeQIBDhUOwLulRxyTUsEoGZwOSAakC7Y_8QUFvR49xauwOBv6nmgKDbo-RaEc3XbLTRnYer373BbtePq0fnpNh3MaEzeCol27a_H2Z_wt8AyE0aNY</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</creator><creatorcontrib>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</creatorcontrib><description>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</description><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2024.110165</identifier><identifier>PMID: 39303855</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Fingolimod Hydrochloride - pharmacology ; Hyperalgesia - drug therapy ; Hyperalgesia - metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Neuralgia - drug therapy ; Neuralgia - metabolism ; Oxadiazoles - pharmacology ; Receptors, Lysosphingolipid - agonists ; Receptors, Lysosphingolipid - metabolism ; Sciatic Nerve - drug effects ; Sciatic Nerve - injuries ; Sciatic Neuropathy - drug therapy ; Sciatic Neuropathy - metabolism ; Sphingosine - analogs & derivatives ; Sphingosine - pharmacology ; Sphingosine 1 Phosphate Receptor Modulators - pharmacology ; Sphingosine-1-Phosphate Receptors - agonists ; Sphingosine-1-Phosphate Receptors - metabolism</subject><ispartof>Neuropharmacology, 2024-12, Vol.261, p.110165</ispartof><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39303855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pondelick, Abby M</creatorcontrib><creatorcontrib>Moncayo, Lauren V</creatorcontrib><creatorcontrib>Donvito, Giulia</creatorcontrib><creatorcontrib>McLane, Virginia D</creatorcontrib><creatorcontrib>Gillespie, James C</creatorcontrib><creatorcontrib>Hauser, Kurt F</creatorcontrib><creatorcontrib>Spiegel, Sarah</creatorcontrib><creatorcontrib>Lichtman, Aron H</creatorcontrib><creatorcontrib>Sim-Selley, Laura J</creatorcontrib><creatorcontrib>Selley, Dana E</creatorcontrib><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</description><subject>Animals</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fingolimod Hydrochloride - pharmacology</subject><subject>Hyperalgesia - drug therapy</subject><subject>Hyperalgesia - metabolism</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neuralgia - drug therapy</subject><subject>Neuralgia - metabolism</subject><subject>Oxadiazoles - pharmacology</subject><subject>Receptors, Lysosphingolipid - agonists</subject><subject>Receptors, Lysosphingolipid - metabolism</subject><subject>Sciatic Nerve - drug effects</subject><subject>Sciatic Nerve - injuries</subject><subject>Sciatic Neuropathy - drug therapy</subject><subject>Sciatic Neuropathy - metabolism</subject><subject>Sphingosine - analogs & derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</subject><subject>Sphingosine-1-Phosphate Receptors - agonists</subject><subject>Sphingosine-1-Phosphate Receptors - metabolism</subject><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFj81OwzAQhC0kRMvPK6A9wiHBzk8TzkDLEYleOFWuvaEbJXZkO0XhtXhBXApnLrua1aeZWcZA8FRwsbhrU4Ojs8NOuj7NeFak4nAvT9hc1FWeVHxRzNi59y3nvKhFfcZm-X3O87os5-zrkby3imQga2CL4QPRQNghSBMokV1n9WRIATYNquDBNtCQebcd9VbDzXL9VmX8NtIaNHo0ngJ9Ht0i-ipeQIBDhUOwLulRxyTUsEoGZwOSAakC7Y_8QUFvR49xauwOBv6nmgKDbo-RaEc3XbLTRnYer373BbtePq0fnpNh3MaEzeCol27a_H2Z_wt8AyE0aNY</recordid><startdate>20241215</startdate><enddate>20241215</enddate><creator>Pondelick, Abby M</creator><creator>Moncayo, Lauren V</creator><creator>Donvito, Giulia</creator><creator>McLane, Virginia D</creator><creator>Gillespie, James C</creator><creator>Hauser, Kurt F</creator><creator>Spiegel, Sarah</creator><creator>Lichtman, Aron H</creator><creator>Sim-Selley, Laura J</creator><creator>Selley, Dana E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20241215</creationdate><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><author>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_393038553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fingolimod Hydrochloride - pharmacology</topic><topic>Hyperalgesia - drug therapy</topic><topic>Hyperalgesia - metabolism</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neuralgia - drug therapy</topic><topic>Neuralgia - metabolism</topic><topic>Oxadiazoles - pharmacology</topic><topic>Receptors, Lysosphingolipid - agonists</topic><topic>Receptors, Lysosphingolipid - metabolism</topic><topic>Sciatic Nerve - drug effects</topic><topic>Sciatic Nerve - injuries</topic><topic>Sciatic Neuropathy - drug therapy</topic><topic>Sciatic Neuropathy - metabolism</topic><topic>Sphingosine - analogs & derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</topic><topic>Sphingosine-1-Phosphate Receptors - agonists</topic><topic>Sphingosine-1-Phosphate Receptors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pondelick, Abby M</creatorcontrib><creatorcontrib>Moncayo, Lauren V</creatorcontrib><creatorcontrib>Donvito, Giulia</creatorcontrib><creatorcontrib>McLane, Virginia D</creatorcontrib><creatorcontrib>Gillespie, James C</creatorcontrib><creatorcontrib>Hauser, Kurt F</creatorcontrib><creatorcontrib>Spiegel, Sarah</creatorcontrib><creatorcontrib>Lichtman, Aron H</creatorcontrib><creatorcontrib>Sim-Selley, Laura J</creatorcontrib><creatorcontrib>Selley, Dana E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pondelick, Abby M</au><au>Moncayo, Lauren V</au><au>Donvito, Giulia</au><au>McLane, Virginia D</au><au>Gillespie, James C</au><au>Hauser, Kurt F</au><au>Spiegel, Sarah</au><au>Lichtman, Aron H</au><au>Sim-Selley, Laura J</au><au>Selley, Dana E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2024-12-15</date><risdate>2024</risdate><volume>261</volume><spage>110165</spage><pages>110165-</pages><eissn>1873-7064</eissn><abstract>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</abstract><cop>England</cop><pmid>39303855</pmid><doi>10.1016/j.neuropharm.2024.110165</doi></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1873-7064 |
ispartof | Neuropharmacology, 2024-12, Vol.261, p.110165 |
issn | 1873-7064 |
language | eng |
recordid | cdi_pubmed_primary_39303855 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Disease Models, Animal Dose-Response Relationship, Drug Female Fingolimod Hydrochloride - pharmacology Hyperalgesia - drug therapy Hyperalgesia - metabolism Male Mice Mice, Inbred C57BL Neuralgia - drug therapy Neuralgia - metabolism Oxadiazoles - pharmacology Receptors, Lysosphingolipid - agonists Receptors, Lysosphingolipid - metabolism Sciatic Nerve - drug effects Sciatic Nerve - injuries Sciatic Neuropathy - drug therapy Sciatic Neuropathy - metabolism Sphingosine - analogs & derivatives Sphingosine - pharmacology Sphingosine 1 Phosphate Receptor Modulators - pharmacology Sphingosine-1-Phosphate Receptors - agonists Sphingosine-1-Phosphate Receptors - metabolism |
title | Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissociation%20between%20the%20anti-allodynic%20effects%20of%20fingolimod%20(FTY720)%20and%20desensitization%20of%20S1P%201%20receptor-mediated%20G-protein%20activation%20in%20a%20mouse%20model%20of%20sciatic%20nerve%20injury&rft.jtitle=Neuropharmacology&rft.au=Pondelick,%20Abby%20M&rft.date=2024-12-15&rft.volume=261&rft.spage=110165&rft.pages=110165-&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2024.110165&rft_dat=%3Cpubmed%3E39303855%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/39303855&rfr_iscdi=true |